RecruitingNCT05534347

Angiogenic Biomarkers in Juvenile Idiopathic Arthritis

Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

300 participants

Start Date

Mar 13, 2023

Study Type

OBSERVATIONAL

Conditions

Juvenile Idiopathic Arthritis (JIA)

Summary

The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.

Eligibility

Min Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Blood sample and a biological treatment called Joint puncture for people with juvenile idiopathic arthritis (jia). The study is currently recruiting participants at 1 location. People eligible for this study include aged 16 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.